Bioceltix S.A. (WSE:BCX)
Poland flag Poland · Delayed Price · Currency is PLN
89.50
+1.60 (1.82%)
Jun 12, 2026, 5:00 PM CET

Bioceltix Statistics

Total Valuation

Bioceltix has a market cap or net worth of PLN 495.14 million. The enterprise value is 434.34 million.

Market Cap495.14M
Enterprise Value 434.34M

Important Dates

The last earnings date was Friday, May 29, 2026.

Earnings Date May 29, 2026
Ex-Dividend Date n/a

Share Statistics

Bioceltix has 5.53 million shares outstanding. The number of shares has increased by 8.77% in one year.

Current Share Class 5.53M
Shares Outstanding 5.53M
Shares Change (YoY) +8.77%
Shares Change (QoQ) +5.95%
Owned by Insiders (%) 6.61%
Owned by Institutions (%) 22.49%
Float 4.44M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio 7.33
P/TBV Ratio 7.33
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 22.56

Current Ratio 22.56
Quick Ratio 22.49
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -144.49

Financial Efficiency

Return on equity (ROE) is -33.35% and return on invested capital (ROIC) is -20.79%.

Return on Equity (ROE) -33.35%
Return on Assets (ROA) -19.46%
Return on Invested Capital (ROIC) -20.79%
Return on Capital Employed (ROCE) -25.26%
Weighted Average Cost of Capital (WACC) 9.23%
Revenue Per Employee n/a
Profits Per Employee -396,346
Employee Count43
Asset Turnover n/a
Inventory Turnover 24.71

Taxes

Income Tax -41,288
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -21.77% in the last 52 weeks. The beta is 0.91, so Bioceltix's price volatility has been similar to the market average.

Beta (5Y) 0.91
52-Week Price Change -21.77%
50-Day Moving Average 84.18
200-Day Moving Average 87.60
Relative Strength Index (RSI) 61.27
Average Volume (20 Days) 6,332

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

Revenue n/a
Gross Profit -2.64M
Operating Income -17.11M
Pretax Income -17.08M
Net Income -17.04M
EBITDA -16.45M
EBIT -17.11M
Earnings Per Share (EPS) -3.31
Full Income Statement

Balance Sheet

The company has 60.79 million in cash and n/a in debt, with a net cash position of 60.79 million or 10.99 per share.

Cash & Cash Equivalents 60.79M
Total Debt n/a
Net Cash 60.79M
Net Cash Per Share 10.99
Equity (Book Value) 67.59M
Book Value Per Share 12.22
Working Capital 62.20M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -17.55 million and capital expenditures -3.15 million, giving a free cash flow of -20.71 million.

Operating Cash Flow -17.55M
Capital Expenditures -3.15M
Depreciation & Amortization 658,411
Net Borrowing -610,443
Free Cash Flow -20.71M
FCF Per Share -3.74
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Bioceltix does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.77%
Shareholder Yield -8.77%
Earnings Yield -3.44%
FCF Yield -4.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1